Multiple Tumor Types

Viewing Page 3 of 6 | Showing Results 21 - 30 of 54

A Phase 1-2, First-in-Human Study of CX-2029 in Adults With Metastatic or Locally Advanced Unresectable Solid Tumors or Diffuse Large B-cell Lymphomas (PROCLAIM-CX-2029)

The purpose of this first-in-human study of CX-2029 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and...

Rachel Sanborn, M.D.
  • Providence Cancer Institute Franz Clinic

0S-15-5 A Pilot Multi-Arm Study of sEphB4-HSA In Combination with Different Chemotherapy Regimens in Patients with Specific Advanced or Metastatic Solid Tumors

This pilot phase Ib trial studies the side effects and best dose of recombinant EphB4-HSA fusion protein when given together with standard...

Diana Hanna, M.D.
  • Hoag Research
  • xSJH Southern California

Genetic drivers of metastases in rare cancers

The objective of this study is to analyze the molecular (DNA, RNA, protein) changes in tumor tissue or blood from people with rare tumors. These...

Michael Demeure, M.D.
  • Hoag Research
  • xSJH Southern California

Implementing a Virtual Tobacco Treatment in Community Oncology Practices: Smoke Free Support Study 2.0.

This phase II trial studies how well smoking cessation treatment plans work in tobacco-dependent cancer patients when delivered virtually as part...

Alison Conlin, M.D.

The Pacific Cancer Research Consortium clinical trials are offered at multiple locations throughout Oregon, Washington, Alaska, California, and Idaho. To find a location near you, please contact the Patient Engagement Center at 844-552-2734.

QUILT-3.055: A Phase IIb, Single-Arm, Multicohort, Open-Label Study of ALT-803 in Combination With PD-1/PD-L1 Checkpoint Inhibitor in Patients Who Have Disease Progression Following an Initial Response to Treatment With PD-1/PD-L1 Checkpoint Inhibitor Therapy

This is a Phase IIb, single-arm, multicohort, open-label multicenter study of ALT-803 in combination with an FDA-approved PD-1/PD-L1 checkpoint...

Rom Leidner, M.D.
  • Providence Cancer Institute Franz Clinic

NEULASTA ONPRO A Prospective Observational Study to Estimate the Incidence of Febrile Neutropenia (FN) Among Subjects With Non-myeloid Malignancies at High Risk for FN and Receiving Neulasta® (pegfilgrastim) Onpro® kit or Other Physician Choice Options for Prophylaxis of FN

To estimate the incidence of FN among subjects treated with myelosuppressive chemotherapy for the treatment of non-myeloid malignancies and...

Ajay Kundra, M.D.
  • Providence Regional Cancer Partnership - Everett

JWC JWCI-18-0401 - John Wayne Cancer Institute Biospecimen and Research Data Repository

The purpose of this study is to collect clinical data and biological specimens (e.g., blood, tumor,cerebrospinal fluid, urine sample, etc.) from...

Jennifer Linehan, M.D.
  • John Wayne Cancer Institute (JWCI)
  • Providence St. Johns Health Center (PSJHC)

A Phase 1, Open-Label, Dose Escalation Study of Pf-04518600 as a Single Agent and In Combination with PF-05082566 In Patients with Selected Locally Advanced or Metastatic Carcinomas?

To assess the safety and tolerability at increasing dose levels of PF-04518600 alone or in combination wtih PF-05082566 in patients with select...

Diana Hanna, M.D.
  • Hoag Research
  • xSJH Southern California

0C 17-1: Phase 1 Multi-center Study of the Safety Pharmacokinetics and Preliminary Efficacy of CBT-101 in Subjects with Advanced Solid Tumors and C-Met Dysregulation

The purpose of this study is to determine the safety, tolerability, and recommended dose of CBT-101 in individuals with advanced solid tumors and...

Diana Hanna, M.D.
  • Hoag Research
  • xSJH Southern California

SJH 15-086-EAY 131: Molecular Analysis for Therapy Choice (MATCH)

This phase II trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have...

Timothy Byun, M.D.
  • St. Joseph Hospital of Orange
  • xSJH Southern California
Viewing Page 3 of 6 | Showing Results 21 - 30 of 54